J. Goldman & Co’s Puma Biotechnology PBYI Stock Holding History

J. Goldman & Co’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-52,000	Closed	-$1.93M	–	387
2017 Q1	$1.93M	Buy	+52,000	New	+$1.9M	0.1%	210

Other funds holding PBYI

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

J. Goldman & Co's PBYI Position: Q1 2021 in Review

J. Goldman & Co sold out of Puma Biotechnology (PBYI) in Q1 2021, closing a stake of 238,617 shares — an estimated $2.45M sold.

J. Goldman & Co first reported a position in PBYI in Q3 2016 and held it in 5 quarters. The position peaked at $3.32M in Q3 2016. 118 funds tracked by Wall St. Rank hold PBYI as of Q1 2021.

J. Goldman & Co reported no remaining Puma Biotechnology position as of Q1 2021 after selling out during the quarter.
J. Goldman & Co sold 238,617 Puma Biotechnology shares in Q1 2021, an estimated $2.45M.
J. Goldman & Co first reported a position in Puma Biotechnology in Q3 2016 and held it in 5 quarters.
J. Goldman & Co's Puma Biotechnology position peaked at $3.32M in Q3 2016.
118 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2021.

Based on J. Goldman & Co's 13F filing for Q1 2021, filed 17 May 2021.